Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

Abstract Introduction Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2017-05, Vol.49 (5), p.568-571
Hauptverfasser:	Lepage, Côme, Dahan, Laetitia, Bouarioua, Nadia, Toumpanakis, Christos, Legoux, Jean-Louis, Le Malicot, Karine, Guimbaud, Rosine, Smith, Denis, Tougeron, David, Lievre, Astrid, Cadiot, Guillaume, Di Fiore, Frédéric, Bouhier-Leporrier, Karine, Hentic, Olivia, Faroux, Roger, Pavel, Marianne, Borbath, Ivan, Valle, Juan W, Rinke, Anja, Scoazec, Jean-Yves, Ducreux, Michel, Walter, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Cancer Clinical Protocols Clinical trial Disease-Free Survival Double-Blind Method Duodenal Neoplasms - drug therapy Duodenal Neoplasms - pathology Duodenopancreatic neuroendocrine tumours Europe Female First line Gastroenterology and Hepatology Humans Life Sciences Maintenance Male Middle Aged Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - pathology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Peptides, Cyclic - administration & dosage Peptides, Cyclic - adverse effects Prospective Studies Quality of Life Somatostatin - administration & dosage Somatostatin - adverse effects Somatostatin - analogs & derivatives Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!